OCTalks: monitoring MRD in hematological malignancy management
Dec 05, 2022•16 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this interview we explore what minimal residual disease (MRD) is in hematological malignancies and how MRD is currently monitored. The interviewees also explain their recent research published in Nanomedicine, which investigates a novel tool to monitor hematological malignancies.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast